Omeros, MannKind-United Therapeutics, and Revance Therapeutics were issued Complete Response Letters from the U.S. Food and Drug Administration.

Shares of Satsuma Pharmaceuticals plunged in trading after the company revealed the migraine treatment STS101 failed to hit co-primary endpoints in a late-stage study.